Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis

Rajesh Subbiah¹, Pow-Li Chia¹, Lorne J. Gula², George J. Klein², Allan C. Skanes², Raymond Yee² and Andrew D. Krahn*²

¹Department of Cardiology, St Vincent’s Hospital, UNSW, Darlinghurst, Sydney, NSW, Australia, 2010; ²Division of Cardiology, University of Western Ontario, London, Ontario, Canada

Abstract: Elucidating the cause of syncope is often a diagnostic challenge. At present, there is a myriad of ambulatory cardiac monitoring modalities available for recording cardiac rhythm during spontaneous symptoms. We provide a comprehensive review of these devices and discuss strategies on how to reach the elusive diagnosis based on current evidence-based recommendations.

Keywords: Syncope, loop recorder, holter monitor, cardiac monitor.

INTRODUCTION

Syncope is defined as a transient loss of consciousness secondary to transient global reduction in cerebral blood flow characterized by rapid onset, short duration and spontaneous complete recovery [1]. Syncope is a frequently encountered clinical conundrum with an estimated lifetime prevalence of up to 35% [2]. Syncope accounts for up to 3% of emergency department consultations and 6% of hospital admissions [3-5]. Although the diagnosis may be evident in a minor number of classic presentations, delineating the underlying cause of unexplained syncope can pose a clinical challenge, which is difficult yet worthwhile, as identification of underlying cardiac disease in patients with syncope is associated with higher rates of mortality and morbidity [6]. The most important aspect of the diagnostic challenge is to obtain a comprehensive history and physical examination [7, 8]. The ideal but often unattainable test for elucidating a cause is obtaining comprehensive physiologic data during spontaneous symptoms. Short of that goal, establishing an accurate symptom–rhythm correlation can often provide a diagnosis, making ambulatory outpatient monitoring a powerful diagnostic tool for the evaluation of cardiac arrhythmias. Evolving technologies have provided a wide array of monitoring options for patients suspected of having cardiac arrhythmias, with each modality differing in duration of monitoring, quality of recording, convenience, and invasiveness.

HOLTER MONITORING

A standard ECG should be ordered for all patients with syncope [3-9]. Short term ECG monitoring via 3 or, in some cases, 12 surface electrodes is the most common initial investigation in patients who present with syncope or palpitations. Typically this occurs in the emergency room or primary care setting with telemetry and continuous monitoring. More recently, however, wireless telemetry offers the possibility of reviewing continuous ECG recordings instantaneously at particular access points [10].

The findings on ECG monitoring must be correlated with symptoms, as heart rate, and even cardiac rhythm, is often uninformative in the absence of clinical correlation. Presyncope is a more common event during ambulatory monitoring but is less likely to be associated with an arrhythmia [11, 12]. Additionally, the ubiquitous nature of presyncope makes it a relatively poor surrogate for the assessment of syncope.

The Holter monitor is a portable battery-operated device that connects to the patient using bipolar electrodes, providing recordings from up to 12 ECG leads. Data are stored in the device using analog or digital storage media. The data are transformed into a digital format and analyzed using interpretive software. Additional markers for patient-activated events and time correlates are included, along with a patient event diary, to allow greater diagnostic accuracy. Continuous ECG monitoring is possible for a maximum of 72 hours (See Fig. 1). This allows the documentation of cardiac rhythm during symptomatic and/or asymptomatic events. Holter monitoring is useful if the clinical history is suggestive of an arrhythmic etiology and the symptoms are frequent enough to be detected within the period of monitoring.

There are, however, a number of disadvantages to Holter monitoring. The major limitation is that patients may not experience symptoms or cardiac arrhythmias during the recording period. The physical size of the device may impair the ability of patients to sleep comfortably or engage in activities that precipitate or reproduce symptoms. Patients are further inconvenienced because the device has to be removed while bathing. There is also considerable variability in patient documentation and recollection of activated events, thereby compromising accurate symptom-rhythm correlation.
It is therefore not surprising that Holter monitoring has a low diagnostic yield. In several large series of patients undergoing 12 or more hours of ambulatory monitoring for investigation of syncope, only 4% had recurrence of symptoms during monitoring [9, 13, 14]. The overall diagnostic yield of Holter monitoring was 19%. Uncommon asymptomatic arrhythmias such as prolonged sinus pauses, atrioventricular block (such as Mobitz type II block), and nonsustained ventricular tachycardia can provide important clues to the diagnosis, often leading to further investigations to rule out structural heart disease and other precipitating factors. While these observations require prompt attention, it is important to interpret the results in the clinical context of the syncopal presentation so that common causes of syncope, such as neurocardiogenic syncope, are not unduly excluded. An example would be nocturnal pauses in a patient with sleep apnea, easily mistaken for intrinsic sinus node disease as a cause of syncope.

It is also important to recognize that normal ambulatory ECG monitoring does not exclude an arrhythmic cause for syncope. Risk stratification scores such as the EGSYS score can be used to estimate the pre-test probability for cardiac syncope [15]. If the pre-test probability is high for an arrhythmic cause, then further investigations such as prolonged monitoring or cardiac electrophysiological studies are required. In a study which evaluated extension of Holter monitoring duration to 72 h [13], there was an increase in the number of asymptomatic arrhythmias detected, but not the overall diagnostic yield.

EXTERNAL EVENT RECORDERS

External event recorders are external devices attached to patients via one to three electrodes with the ability to provide a longer period of monitoring than the standard Holter monitor. They may be patient activated or triggered automatically. The 3 main types of external event recorders are transtelephonic monitors, external cardiac loop recorders and mobile automated cardiac outpatient telemetry (MCOT) monitors.

Transtelephonic ECG monitors are recording devices that transmit data via an analog phone line to a base station (Fig. 2). The signal is then converted to an interpretable recording that is displayed or printed as a single lead rhythm strip. The ECG signals are collected on a real-time 1-2 minute loop.
An external cardiac loop recorder continuously records and stores an external single modified limb lead electrogram with a 4-18 minute memory buffer (Fig. 3, left). After the onset of spontaneous symptoms the patient activates the device, which stores the previous 3-14 minutes, and the following 1-4 minutes, of recorded information. The captured rhythm strip can subsequently be uploaded and analyzed (Fig. 4) and often provides critical information regarding the onset of the arrhythmia. This system can be used for weeks to months provided weekly battery changes are performed. The recording device is attached with two leads to the patient’s chest wall and needs to be removed for bathing, and can be uncomfortable during sleep. To allow detection of asymptomatic arrhythmias, external loop recorders with an automatic trigger algorithm have been introduced.

MCOT is the most recent advancement in external ambulatory arrhythmia monitoring [16]. Patients wear two to three

Fig. (3). Loop Recorders. An external loop recorder (left) with cables that attach to the patient. The record button is pressed in the event of symptoms to store the previous 9 minutes, and the ensuing minute. The phone receiver is also placed over this button to transmit data over an analog phone line. An implantable cardiac monitor (center) and patient activator (right). The patient activator is used to “freeze” symptomatic events that are retrieved with a pacemaker programmer. Automatic events can also be captured (see text for discussion).

Fig. (4). External Loop Recorder Tracing. Sinus rhythm during presyncope is recorded in a 43-year-old female with recurrent unexplained syncope and presyncope. The fluctuation in heart rate is suggestive of neurocardiogenic syncope.
chest leads attached to a portable sensor that continuously records rhythm strips and transmits the ECG data of pre-specified arrhythmias in real-time to a communication hub at the patient’s home. If the algorithms in the hub detect a significant arrhythmia in keeping with previously designated physician thresholds or if the patient activates the sensor to report symptoms, the monitor automatically transmits the patient’s ECG data to the central station using wireless communications. The data may be screened 24 hours a day by central monitoring station technicians, with potential immediate or deferred referral to the attending physician for evaluation of symptoms, rate and/or rhythm changes. The major drawback of this modality is patient compliance to wearing the device.

Linzer et al. reported the use of patient-activated loop recorders in 57 patients with syncope and non-diagnostic findings on history, physical examination and 24 hour Holter monitoring [17, 18]. A diagnosis was obtained in 14 of 32 patients who had recurrence of symptoms. In the remaining 18 patients, device malfunction, patient non-compliance or inability to activate the recorder was responsible for the lack of diagnosis. Other studies have also reported similar findings [18, 19] and demonstrated that loop recorders are complementary to 24 hour ambulatory electrocardiographic monitoring. The diagnostic yield for external loop recorders in these three studies [17-19] ranged from 24%-47%, with highest yield in patients with palpitations.

A prospective randomized clinical trial compared the utility of external loop recorders to conventional Holter monitoring in a community based referral population with syncpe and presyncope [20]. Not surprisingly, the ability to obtain a symptom-rhythm correlation was 22% for Holter monitoring and 56% for the external loop recorder (p < 0.001), with duration of monitoring of 48 hours and 4 weeks, respectively. A higher diagnostic yield was also obtained among patients randomized to Holter monitoring who remained undiagnosed and crossed-over to use of a loop recorder. This trial suggests that loop recorders should be considered as first line monitoring when attempting to establish a symptom rhythm correlation in the initial workup of patients with syncope, unless symptoms are very frequent, or a rhythm sample of 24-48 hours is sought. Twenty-four percent of loop recorder patients failed to activate the device properly, suggesting limited usefulness in some patients [20]. Analysis of factors pertaining to use of external loop recorders has revealed a particularly low diagnostic yield among patients who are unfamiliar with technology, live alone, or have low motivation for achieving a diagnosis [21]. Reiffel et al. [22] retrospectively compared the results obtained by Holter monitoring, loop recording and auto-triggered loop recording in 600 patients from a database of approximately 100,000 patients. The auto-triggered loop recording approach provided a higher yield of diagnostic events (36%) compared to loop recording (17%) and Holter monitoring (6.2%).

External event recorders appear to have the greatest role in motivated patients with frequent spontaneous symptoms that are likely to recur within 4-6 weeks. Given that they are non-invasive and cost effective, they should be considered in all patients in whom an arrhythmic cause for syncope is suspected, keeping in mind that long-term compliance with these devices can be challenging because of electrode and skin-related problems and waning of patient motivation in the absence of recurrent symptoms.

**IMPLANTABLE CARDIAC MONITORS**

The implantable cardiac monitor (ICM) has become the investigative tool of choice in recurrent unexplained syncope and the St Jude Medical Confirm™ series. A typical ICM (Medtronic Reveal DX Model 9528) has a pair of sensing electrodes with 4-cm spacing on a small elongated recording device 6.2 cm long, 1.9 cm wide, and 0.8 cm thick, weighing 15 g (Fig. 3, center). The projected battery longevity is 36 months. The device can be implanted subcutaneously in the left chest wall with local anesthesia and antibiotic prophylaxis.

Prior to implantation, cutaneous mapping should be performed to optimize the sensed signal and avoid T-wave oversensing, which can be falsely interpreted as a high rate episode. An adequate signal can usually be obtained anywhere in the left hemithorax [23]. Grubb et al. [24] described an anatomic-based approach to ICM placement in 63 patients that did not require cutaneous mapping. Each underwent implantation of ILR in the left upper chest area midway between the supraclavicular notch and left breast area. In all patients, adequate electrocardiographic tracings were obtained at implant without need for preoperative cutaneous mapping. The mean P wave amplitude was 0.12 ± 0.20 mV at implant and at follow-up (6-14 months post-implant), the amplitude was 0.11 ± 0.19 mV. The peak-to-peak QRS amplitude was 0.48 ± 0.15 mV at implant and 0.44 ± 0.16 mV at a follow-up of 6-14 months. This strategy has not been validated.

The recorded bipolar signal is stored in the device as 42 minutes of compressed signal. A compressed signal maximizes memory capability with only marginal loss of quality. The patient, along with a spouse, family member or friend is instructed in the use of the activator at the time of implant. Once an episode is recorded (i.e. a presyncopal or syncopal event occurs) the memory is “frozen” by the patient or a relative using a non-magnetic handheld activator (Fig. 3, right). The episode is then uploaded for interrogation to a pacemaker programmer. Although heart rate is usually easily ascertained, p waves can occasionally be challenging to interpret. The most recent version of the ICM has programmable automatic detection of tachycardia-bradycardia arrhythmias, pauses, and allows for comprehensive remote monitoring without an office visit. The Medtronic CareLink® Home Monitor allows patients to transmit data from their Medtronic Reveal® ICMs over a standard
phone line for review by their physicians. The St Jude Medical Confirm™ ICMs also has transtelephonic monitoring capability, enabling transmission of timely and accurate data. These features enhance the utility of ICMs, especially if patients have frequent saved events or live in remote areas where travel to a dedicated clinic is time consuming and costly.

A classification system for recorded events has been proposed by Brignole et al. [25] (Table 1) that categorizes the probable mechanism of syncope according to the pattern of bradycardia recorded during spontaneous syncope. An example of the cardioinhibitory component of neurocardiogenic or vasovagal syncope is illustrated in (Fig. 5). This would be considered a 1A response. Figure 6 illustrates a

| Classification | Sinus Rate | AV Node | Comment | Presumed Mechanism |
|----------------|------------|---------|---------|--------------------|
| Asystole (RR>3 sec) | | | | |
| 1A | Arrest | Normal | Progressive sinus bradycardia with sinus arrest: | vasovagal |
| 1B | Bradycardia | AV block | AV block with associated sinus bradycardia: | vasovagal |
| 1C | Normal or tachycardia | AV block | Abrupt AV block without sinus slowing | intrinsic AV node disease |
| Bradycardia | | | | |
| 2A | Decrease>30% | Normal | vasovagal |
| 2B | HR<40 for >10 seconds | Normal | vasovagal |
| Minimal HR change | | | | |
| 3A | <10% variation | Normal | non-cardiac cause | vasovagal |
| 3B | HR increase or decrease 10-30%, not <40 or >120 bpm | Normal | non-cardiac cause | vasovagal |
| Tachycardia | | | | |
| 4A | Progressive tachycardia | Normal | Sinus acceleration typical | orthostatic intolerance or non-cardiac cause |
| 4B | N/A | Normal | Atrial fibrillation | Mixed – may be a component of vasovagal as well |
| 4C | N/A | Normal | Supraventricular tachycardia | |
| 4D | N/A | Normal | Ventricular tachycardia | |

HR = heart rate, N/A = not applicable.
Adapted from Brignole M, Moya A, Menozzi C, Garcia-Civera R, Sutton R. Proposed electrocardiographic classification of spontaneous syncope documented by an implantable loop recorder. Europace. Jan 2005;7(1):14-18 with permission.

Fig. (5). Automatic Event Detection from an ICM. This is a typical tracing of an event captured by an ICM during syncope in a patient. The arrow and letter A denotes automatic activation when the device detects a 3 second pause. Each line constitutes 10 seconds of a single lead rhythm strip. Note the slowing of the sinus rate prior to onset of a prolonged pause, which resulted in syncope. This is consistent with the diagnosis of neurocardiogenic syncope (ISSUE classification 1A).
primary bradycardia (1C response), highly suggestive of intrinsic AV node disease. This classification is useful for research purposes for event classification, and is useful in directing therapy once validated.

Currently there are several studies establishing the utility of ICM in the diagnosis of syncope [25-30]. One of these studies is a multi-centre study of 206 patients [29]. The majority of patients had undergone non-invasive and invasive testing including head-up tilt testing and electrophysiologic studies. The etiology of syncope was arrhythmic in 22% of patients [29]. Bradycardia was the most commonly detected arrhythmia (17% vs. 6% tachycardia), usually leading to pacemaker implantation [29].

In a group of patients with ongoing seizures despite anti-convulsant therapy, Zaidi et al. performed cardiac assessment including head-up tilt testing and carotid sinus massage in all patients, and implantation of an ICM in ten patients [31, 32]. Two of the 10 patients with an ICM had marked bradycardia preceding a seizure; one due to sinus pauses and the other due to heart block. Importantly, this study suggested seizures that are atypical in presentation may have a cardiovascular cause in as many as 42% of cases, and cardiovascular assessment including long term cardiac monitoring with an ICM may play a role in select patients with atypical seizures.

In three studies [3, 33, 34] from the International Study on Syncope of Uncertain Etiology (ISSUE) investigators, ICMs were implanted in different groups of patients with syncope to assess cardiac rhythm during episodes, after conventional testing. The first study involved tilt tests in 111 patients with unexplained syncope, and ICMs implanted after the tilt test, regardless of result [33]. Syncope recurred in 34% of patients in both the tilt positive and tilt negative group, with marked bradycardia or asystole being the most commonly recorded arrhythmia during follow-up (46% and 62% respectively). The heart rate during tilt testing did not predict spontaneous heart rate response, with a much higher incidence of asystole than expected based on demographics or tilt. This study suggests that observations during tilt testing correlate poorly with cardiac rhythm during spontaneous syncope, and that bradycardia is more common in this population than previously recognized. An example of the cardio-inhibitory component of vasodepressor syncope is illustrated in (Fig. 5).

In the second study, 52 patients with syncope, bundle branch block and negative electrophysiologic testing underwent ICM implantation [3]. Syncope recurred in 22 of the 52 patients with conduction system disease. Long term monitoring demonstrated marked bradycardia mainly attributed to complete AV block in 17, while it excluded AV block in 2. This study confirmed that negative electrophysiologic testing does not exclude intermittent complete AV block, and that prolonged monitoring or consideration of permanent pacing is reasonable in this population.

The third study examined the spontaneous rhythm in 35 patients with syncope, overt heart disease and negative electrophysiologic testing [34]. The underlying heart disease was predominantly ischemic or hypertrophic cardiomyopathy with moderate left ventricular dysfunction. Although previous studies have suggested that patients with negative electrophysiologic testing have a better prognosis, there remains concern regarding risk of ventricular tachycardia in this group. Symptoms recurred in 19 of the 35 patients (54%), with bradycardia in 4, supraventricular tachyarrhythmias in 5 and ventricular tachycardia in only 1 patient. There were no sudden deaths during 16 ±11 months of follow-up.

ISSUE 2 was a prospective, multicenter observational study that investigated the efficacy of therapies based on ICM diagnosis of recurrent suspected neurocardiogenic syncope [35]. The 1-year recurrence rate of syncope in 392 patients was 33%. Among 103 patients with a documented episode, 53 patients were randomized to specific therapy; 47 receiving a pacemaker due to asystole and 6 receiving anti-tachyarrhythmia therapy (catheter ablation: 4, implantable defibrillator: 1, anti-arrhythmic drug: 1). The remaining 50
patients did not receive specific therapy. The 1-year recurrence rate among the 53 patients assigned to a specific therapy was 10% compared with 41% in the patients without specific therapy. The 1-year recurrence rate in patients with pacemakers was 5%. The authors concluded that a strategy based on diagnostic information from early ICM implant, with therapy delayed until documentation of syncope, allows safe, specific, and effective therapy in patients with neurocardiogenic syncope.

PICTURE (Place of Reveal In the Care pathway and Treatment of patients with Unexplained Recurrent Syncope) is the largest prospective, multicenter, observational study to date to evaluate the usage and diagnostic effectiveness of ICMs in the everyday clinical diagnostic work-up of patients with unexplained syncope [36]. Patients were followed up until the first recurrence of syncope leading to a diagnosis or for ≥1 year. In the course of the study, patients were evaluated by an average of 3 different specialists for syncope management and underwent a median of 13 tests (range 9–20). Follow-up visit data were available for 570 subjects. The percentages of patients with recurrence of syncope were 19, 26, and 36% after 3, 6, and 12 months, respectively. Of 218 events within the study, ICM-guided diagnosis was obtained in 170 cases (78%), of which 128 (75%) were cardiac. The results revealed that patients underwent a large number of diagnostic tests before an ICM implant and the use of an ICM was associated with a high diagnostic yield in the overall population with unexplained syncope. Together, these findings imply that if an ICM is implanted early, a reduced number of tests might be needed.

There have been two randomized trials that compared the role of the ICM with a conventional testing strategy for syncope. The Randomized Assessment of Syncope Trial (RAST) [27, 37] was a prospective randomized trial that compared early use of the ICM for prolonged monitoring to conventional testing in patients undergoing a cardiac workup for unexplained syncope. A diagnosis was obtained in 14 of 27 patients randomized to one year ICM monitoring, compared to 6 of 30 undergoing conventional testing with external loop recorder, tilt test and electrophysiology study (52% vs. 20%, p=0.012). Overall, prolonged monitoring was more likely to result in a diagnosis than conventional testing (55% vs. 19%, p=0.0014). Bradycardia was detected in 14 patients undergoing monitoring, compared to 3 patients with conventional testing (40% vs. 8%, p=0.005). These data highlight the diverse etiology of syncope, and also illustrate the limitations of conventional diagnostic techniques. Although there is clear selection bias in enrollment of patients referred to an electrophysiologist for workup, this study suggests that tilt testing has a modest yield when applied to all patients undergoing investigation for unexplained syncope, and that electrophysiologic testing is of very limited utility in patients with preserved left ventricular function. Also, in patients with a negative electrophysiologic study for suspected arrhythmia tilt testing has been shown to be of little value in predicting the mechanism of syncope [38].

The other randomized study is the Eastbourne Syncope Assessment Study (EaSyAS) [39]. Two hundred and one patients presenting to a single institution with recurrent syncope without a definite diagnosis following a basic clinical work-up were randomly assigned to ICM implantation (n=103) or conventional investigation and management (n=98). Over a mean follow-up period of 276 ± 134 days, there were further syncopal events in 43% of the ICM group compared with 33% of the conventional strategy group. Thirty-three patients in the ICM group and four in the conventional strategy group received an electrocardiographic diagnosis (33% vs 4%, HR 8.93, 95% CI 3.17 to 25.2, p<0.0001). Seventeen-month follow-up data from the same group of patients were reported in 2006 [40]. Forty-three per cent of the ICM group and 6% of the conventional testing strategy group received an electrocardiographic diagnosis (HR 6.53, 95% CI 3.73 to 11.4, p<0.0001).

### STRATEGIES FOR CHOOSING PROLONGED MONITORING

Table 2 summarizes the comparative advantages, limitations and indications for the various modes of ambulatory electrocardiographic monitoring. The literature, including recently updated guidelines and position papers from the European Society of Cardiology and European Heart Rhythm Association [1,41], supports the early use of the ICM in an initial phase of the diagnostic work-up of patients with recurrent unexplained syncope. The optimal patient for prolonged monitoring with an external event recorder or ICM has symptoms suspicious for arrhythmia; namely abrupt onset with minimal prodrome, typically brief loss of consciousness and complete resolution of symptoms within seconds to minutes. ISSUE 2 suggested that documentation of the cardioinhibitory component of vasovagal syncope might identify a group of patients that respond well to pacing. Brignole and colleagues addressed this hypothesis, by evaluating the effect of placebo pacing therapy [42]. Syncope recurred in 38% of patients randomized to placebo vs. 34% randomized to no treatment. The recurrence rate with active cardiac pacing was 15%. The authors suggested that the use of specific selection criteria for pacing, such as characteristics of the observed cardioinhibitory reflex may identify those who will respond to cardiac pacing [42].

After clinical assessment, including assessment of left ventricular function, a decision must be made if the patient’s underlying condition is potentially life threatening. All reports using the ICM have suggested a low incidence of life-threatening arrhythmia or significant morbidity with a prolonged monitoring strategy. This suggests a good prognosis for patients with recurrent unexplained syncope in the absence of left ventricular dysfunction or with negative electrophysiologic testing. This finding was particularly striking in the negative electrophysiologic testing arm of the ISSUE study (see discussion above).

Lastly, syncope fails to recur during long term monitoring in almost one third of patients even in the presence of frequent episodes prior to ICM implantation. This suggests that the cause of syncope in some instances is self-limiting, reflecting a transient physiologic abnormality.
Table 2.  Comparison of ambulatory electrocardiographic monitoring devices.

|                               | Advantages                                      | Limitations                                        | Indications                                      | Diagnostic yield               |
|-------------------------------|-------------------------------------------------|----------------------------------------------------|-------------------------------------------------|---------------------------------|
| Holter monitor                | Low cost; Continuous monitoring                 | Short duration of monitoring with low diagnostic yield | Patients with very frequent symptoms (≥1 per week) | 6%-22% [9, 20, 22]             |
| Transtelephonic monitor       | Low cost                                        | Poor electrocardiographic recordings; Short lasting arrhythmias are not recorded; Patient activation required; Poor patient compliance to wearing device | Compliant patients with intersymptom interval ≤ 4 weeks | 23%-42% [17-19]             |
| External loop recorder        | Retrospective and prospective electrocardiographic records; Possibility to record asymptomatic arrhythmias automatically | Poor electrocardiographic recordings; Poor patient compliance to wearing device; Continual device maintenance required | Compliant patients with intersymptom interval ≤ 4 weeks | 24%-47% [17-19]             |
| Mobile cardiac outpatient telemetry | Continuous monitoring; Patient activation to report symptoms | Poor patient compliance to wearing device; Continual device maintenance required | Compliant patients with intersymptom interval ≤ 4 weeks | 41%-61% [16]             |
| Implantable cardiac monitor   | Prolonged monitoring without external electrodes; Highest diagnostic yield | Invasive implantation with risk of local complications; High cost | Early phase of evaluation of patients with recurrent syncope of uncertain origin who have absence of high-risk criteria that require immediate hospitalization or intensive evaluation and a likely recurrence within device battery longevity | 43%-78% [25-30]             |

CONCLUSIONS
Syncope, although relatively common, remains a significant diagnostic dilemma for clinicians, despite advances in knowledge pertaining to mechanism. A careful history and physical examination are crucial in the course of differentiating syncope from other causes of loss of consciousness. The ultimate diagnostic goal is to correlate symptoms to rhythm disturbances, and accurate attainment of this goal requires the judicious use of monitoring strategies. Ambulatory cardiac monitoring has provided a powerful means to elucidate etiology of presyncope or syncope. The choice of ambulatory monitoring modality is influenced by index of suspicion of cardiac arrhythmias, frequency and nature of symptoms and diagnostic yield of the monitoring device. The clinician should consider early use of ICMs and when an arrhythmia is suspected based on clinical presentation and initial non-invasive testing.

CONFLICT OF INTEREST
Dr George J. Klein, Dr Raymond Yee and Dr Andrew D Krahn are consultants to Medtronic.

ACKNOWLEDGEMENTS
Declared none.

DISCLOSURE
This manuscript is an updated version of the following review article:

Subbiah R, Gula LJ, Klein GJ, Skanes AC, Yee R, Krahn AD. Syncope: review of monitoring modalities. Curr Cardiol Rev. 2008; 4(1): 41-8.

REFERENCES
[1] Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30(21): 2631-71
[2] Ganzbeoom KS, Mainthu G, Reitsma JB, et al. Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol 2006; 17(11): 1172-6.
[3] Briggle M, Menozzi C, Moya A, et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation 2001; 104(17): 2045-50.
[4] Farwell D, Sulke N. How do we diagnose syncope? J Cardiovasc Electrophysiol 2002; 13(1 Suppl): S9-13.
[5] Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347(12): 878-85.
[6] Kapoor WN, Hanusa BH. Is syncope a risk factor for poor outcomes? Comparison of patients with and without syncope. Am J Cardiol Med 1996; 100(6): 646-55.
[7] Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol 2002; 40(1): 142-8.
[8] Alboni P, Briggle M, Menozzi C, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol 2001; 37(7): 1921-8.
[9] Linzer M, Yang EH, Estes NA, III, et al. Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med 1997; 127(1): 76-86.
[10] Schickendantz S, Pillecamp F, Emmel M, et al. Wireless Holter transmission in suspected dysrhythmias. J Electrocardiol 2006; 39(4 Suppl): S54-6.
[11] Kapoor WN. Evaluation and management of the patient with syncope. JAMA 1992; 268(18): 2553-60.
Cardiac Monitoring in Patients with Syncope

[12] Krahn AD, Klein GJ, Yee R, et al. Predictive value of presyncope in patients monitored for assessment of syncope. Am Heart J 2001; 141(5): 817-21.

[13] Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990; 150(5): 1073-8.

[14] Waktare JE, Malik M. Holter, loop recorder, and event counter capabilities of implanted devices. Pacing Clin Electrophysiol 1997; 20(10 Pt 2): 2658-69.

[15] Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. Heart 2008; 94: 1620-6.

[16] Joshi AR, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol 2005; 95: 878-81.

[17] Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol 1990; 66(2): 214-9.

[18] Cumbee SR, Pryor RE, Linzer M. Cardiac loop ECG recording: a new noninvasive diagnostic test in recurrent syncope. South Med J 1990; 83(1): 39-43.

[19] Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory electrocardiograph device with a solid-state memory loop. Br Heart J 1987; 58(3): 251-3.

[20] Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders versus Holter monitors in patients with syncope or presyncope. Am J Med 2003; 115(1): 1-5.

[21] Gula LJ, Krahn AD, Massel D, et al. External loop recorders: determinants of diagnostic yield in patients with syncope. Am Heart J 2004; 147(4): 644-8.

[22] Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. Am J Cardiol 2005; 95(9): 1055-9.

[23] Krahn AD, Klein GJ, Yee R, et al. Maturation of the sensed electrogram amplitude over time in a new substituentable implantable loop recorder. Pacing Clin Electrophysiol 1997; 20(6): 1686-90.

[24] Grubb BP, Welch M, Kanjwal K, et al. An anatomic-based approach for the placement of implantable loop recorders. Pacing Clin Electrophysiol 2010; 33(9): 1149-52.

[25] Brigonole M, Menozzi C, Maggi R, et al. The usage and diagnostic yield of the implantable loop-recorder in detection of the mechanism of syncope and in guiding effective antiarrhythmic therapy in older people. Europace 2005; 7(3): 273-9.

[26] Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation 1999; 99(3): 406-10.

[27] Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001; 104(1): 46-51.

[28] Krahn AD, Klein GJ, Yee R, et al. Final results from a pilot study with an implantable loop recorder to determine the etiology of syncope in patients with negative noninvasive and invasive testing. Am J Cardiol 1998; 82(1): 117-9.

[29] Krahn AD, Klein GJ, Fitzpatrick A, et al. Predicting the outcome of patients with unexplained syncope undergoing prolonged monitoring. Pacing Clin Electrophysiol 2002; 25(1): 37-41.

[30] Lombardi F, Calosso E, Masioli G, et al. Utility of implantable loop recorder (Reveal Plus) in the diagnosis of unexplained syncope. Europace 2005; 7(1): 19-24.

[31] Zaidi A, Clough P, Cooper P, et al. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000; 36(1): 181-4.

[32] Zaidi A, Clough P, Mawer G, et al. Accurate diagnosis of convulsiv syncope: role of an implantable subcutaneous ECG monitor. Seizure 1999; 8(3): 184-6.

[33] Moya A, Brigonole M, Menozzi C, et al. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation 2001; 104(11): 1261-7.

[34] Menozzi C, Brigonole M, Garcia-Civera R, et al. Mechanism of syncope in patients with heart disease and negative electrophysiologic test. Circulation 2002; 105(23): 2741-5.

[35] Brigonole M, Sutton R, Menozzi C, et al. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J 2006; 27(9): 1085-92.

[36] Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTuRE registry. Euro 2011; 13(2): 262-9.

[37] Krahn AD, Klein GJ, Yee R, et al. Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial. J Am Coll Cardiol 2003; 42(3): 495-501.

[38] Garcia-Civera R, Ruiz-Granell R, Morell-Cabedo S, et al. Significance of tilt table testing in patients with suspected arrhythmic syncope and negative electrophysiologic study. J Cardiovasc Electrophysiology 2005; 16(9): 938-42.

[39] Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. Europace 2004; 25: 1257-63.

[40] Farwell DJ, Freemantle N, Sulke AN. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J 2006; 27: 351-6.

[41] Brigonole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009; 11: 671-87.

[42] Brigonole M, Sutton R. Pacing for neurally mediated syncope: is placebo powerless? Europace 2007; 9(1): 31-3.